C

Cencora

Distributes medicines and supports patient care

Endpoint Engineer - Endpoint Engineering

Full-TimeUpdated on 10/23/2026Deadline 11/13/26
No salary listed
Expert
Pennsylvania, USA
Remote
IT OperationsSystem Administration

About the job

Requirements
  • 20+ years of experience in endpoint engineering, primarily focused on Active Directory, Group Policy Management, and Intune policies for endpoints and users.
  • Expertise managing endpoint platforms such as Microsoft Endpoint Configuration Manager (MECM), Intune, Jamf, NinjaOne, and similar tools.
  • Ability to transition on-premises policies to cloud-based solutions, particularly Intune, and prepare for Microsoft Entra migrations.
  • Experience with Microsoft cloud-native technologies, including Microsoft Graph API, Azure Active Directory, and related endpoint-management and automation tools.
  • Troubleshooting skills across endpoint engineering platforms, operating systems, and user domains.
  • Experience navigating large global organizations with tens of thousands of users and endpoints, including integrated and non-integrated entities.
  • Ability to manage multiple responsibilities, projects, and demands across time zones in a dynamic global environment.
  • Ability to work independently with minimal oversight and drive initiatives while maintaining accountability and focus.
  • Ability to collaborate across organizational levels and align infrastructure, security, and business teams.
Responsibilities
  • Design, implement, and manage Active Directory and Group Policies to support endpoint and user requirements across a global organization.
  • Develop, implement, and optimize Intune policies for endpoint and user management in alignment with organizational objectives and compliance standards.
  • Lead the transition of on-premises policies to cloud-based solutions, including Microsoft Intune, in preparation for future Microsoft Entra migration.
  • Harmonize application owners' business requirements with endpoint policies to balance usability and security.
  • Ensure endpoint policies are scalable and adaptable for a large global organization with tens of thousands of users and endpoints.
  • Manage and optimize endpoint management platforms, including MECM, Microsoft Intune, Jamf for macOS management, and NinjaOne for remote monitoring and management.
  • Use Microsoft cloud-native technologies, including Microsoft Graph API, to streamline and automate endpoint management tasks.
  • Troubleshoot and resolve complex endpoint engineering issues across platforms and operating systems, including Windows, macOS, and mobile devices.
  • Stay current with endpoint engineering technologies and trends to improve the organization's endpoint strategy.
  • Collaborate with infrastructure teams, application owners, and business stakeholders to implement endpoint solutions.
  • Represent user experience in cross-domain discussions and advocate for end-user productivity while minimizing disruption during policy changes.
  • Work with security teams on ad hoc requests to align endpoint solutions with security goals while prioritizing usability.
  • Liaise between infrastructure and security teams to support communication and alignment on endpoint-related initiatives.
  • Address security-related requests and collaborate with security teams to ensure endpoint policies adhere to Center for Internet Security (CIS) Levels 1 and 2 benchmarks.
  • Guide endpoint hardening practices to help ensure systems are secure, resilient, and compliant while prioritizing user experience.
  • Participate in security meetings as needed and provide technical expertise on endpoint engineering strategies.
  • Serve as a subject matter expert in Active Directory, Group Policy, and Intune policies, mentoring and guiding junior engineers.
  • Translate technical concepts into actionable insights for non-technical stakeholders.
  • Drive strategic endpoint management initiatives aligned with organizational goals and priorities.
Desired Qualifications
  • Experience working in enterprise-scale environments with complex endpoint requirements.
  • Microsoft Certified: Endpoint Administrator Associate, Azure Solutions Architect, or similar certification.
  • Familiarity with Microsoft Entra and its integration into endpoint and identity management strategies.

About the company

Cencora buys and distributes medicines for pharmacies, hospitals and physician practices, while helping drug manufacturers bring treatments to patients. Its businesses combine wholesale supply networks with specialty distribution for complex therapies and services that support prescribing and patient access. Customers order medicines through its distribution systems, and its teams manage sourcing, storage and delivery alongside pharmacy operations and manufacturer support. It earns revenue from pharmaceutical sales and fees for logistics and healthcare services. The parent company was formed in 2001 through the merger that created AmerisourceBergen, adopted the Cencora name in 2023, and is headquartered in Conshohocken, Pennsylvania.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

2001

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy contracts deepen customer ties: Cencora negotiates insurer agreements and handles administrative work through its managed-care networks.
  • Eligible US staff gain retirement support: Cencora counts student-loan payments toward its employer match, up to 4% of pay.
  • Drug demand expands sales: Cencora reported 5.1% quarterly revenue growth in August 2026, led by higher US volumes.

What critics are saying

  • Customer dependence concentrates risk: Walgreens and Boots supplied 25% of Cencora's fiscal 2025 revenue, reported in November 2025.
  • Legal liabilities tie up cash: Cencora's November 2025 filing recorded $4.3 billion in opioid settlements, payable over 13 years.
  • Warehouse work is physical: Cencora's day-shift associate listing requires repeated lifting up to 50 pounds and overtime availability.

What makes Cencora unique

  • Independent pharmacies get a shared brand: Cencora's Good Neighbor Pharmacy franchise supports their merchandising and store identity.
  • Specialty shipments use reusable packaging: Cencora's World Courier Cocoon containers combine passive temperature control with live location monitoring.
  • Medicines arrive ready for bedside checks: Cencora's American Health Packaging sells barcoded unit doses that support hospital scanning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Parental Leave
  • Adoption Assistance
  • Infertility Coverage
  • Family Planning Benefits
  • Behavioral Health Solutions
  • Professional Development Budget
  • Training Programs

Company News

Financial News
Oct 21st, 2026
Cencora to buy American Oncology Network in $2.4bn deal

Cencora agrees to buy American Oncology Network for $2.4bn enterprise value, but a stockholder rollover means it may land only 75% of the company.

Yahoo Finance
Oct 16th, 2026
Cencora stock: $332.8B revenue, 14.4% EPS growth and 50.2% ROIC

Cencora, the pharmaceutical distributor formerly known as AmerisourceBergen, has risen 6% to $341.69 per share over the past six months. The S&P 500 gained 9.7% in the same period. The New York Stock Exchange-listed company (NYSE:COR) connects drug manufacturers with healthcare providers and offers logistics, data analytics, and consulting services. It rebranded in 2023. Its revenue reached $332.8 billion over the past 12 months, giving it scale and bargaining power with suppliers. That matters in a low-margin, volume-driven business. Earnings per share grew at a 14.4% compound annual rate over five years, outpacing 10.2% annualised revenue growth. Its five-year average return on invested capital was 50.2%. The shares trade at 17.4 times forward earnings.

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.